Syntimmune Closes $50 Million Series B Financing led by Apple Tree Partners
Syntimmune, Inc., a clinical-stage biotechnology company focused on FcRn biology, today announced a $50 million Series B financing led by Apple Tree Partners, which has committed $48 million to the round, with additional participation from other existing investors. The funds from the Series B financing will further advance Syntimmune’s clinical development program.
Most Recent Posts:
Meet the 2023 Commercialization and Inclusive Leadership Program Participants
Congratulations to all the participants chosen to attend the 2023 Mass General Brigham Commercialization and Inclusive Leadership…
Connect with global leaders in healthcare innovation at the 2023 World Medical Innovation Forum June 12-14
The annual World Medical Innovation Forum is being held in person at the Westin Seaport District in…
Innovation Employees Celebrate Years of Service Milestones
More than 500 Mass General Brigham employees were honored in the recent 26th annual Enterprise Services Employee…
